2015 Fiscal Year Final Research Report
Development of DNA-aptamer raised against RAGE and its clinical application for cardiovascular disease and cancer
| Project/Area Number |
25293127
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MATSUI TAKANORI 久留米大, 医学部, 講師 (10425233)
UEDA SHIN-ICHIRO 久留米大, 医学部, 助教 (00412502)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 糖尿病合併症治療 / DNAアプタマー / 核酸医薬品 / 終末糖化産物 / 終末糖化産物受容体 |
|---|
| Outline of Final Research Achievements |
Advanced glycation end products (AGEs) and their receptor (RAGE) play a role in diabetes-associated complications, such as diabetic nephropathy and cancer. We screened DNA aptamer directed against RAGE (RAGE-aptamer) in vitro, and examined its effects on renal injury in streptozotocin-induced diabetic rats and melanoma growth in nude mice. Urinary albumin and 8-hydroxy-2’-deoxy-guanosine, AGEs and RAGE levels were increased, and enhanced glomerular extracellular matrix accumulation were observed in diabetic rats, all of which were prevented by RAGE-aptamer. Moreover, RAGE-aptamer inhibited tumor growth in nude mice, and decreased expression levels of proliferating nuclear antigen, CD31 and Mac-3, markers of endothelial cells and macrophages, respectively. RAGE-aptamer may be a novel therapeutic agent for diabetes-associated complications.
|
| Free Research Field |
糖尿病学
|
